{"entity":{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","aka":["protein phosphatase 2 scaffold subunit Aalpha","Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform","PR65A","PP2A-Aalpha","PP2AA"],"tldr":"PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Upon interaction with GNA12 promotes dephosphorylation of microtubule associated protein TAU/MAPT. Required for proper chromosome segregation and for centromeric localisation of SGO1 in mitosis.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Ipilimumab/Nivolumab Regimen and Durvalumab/Tremelimumab Regimen. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes affected pathway 0.89, literature 0.89, genetic association 0.00, somatic mutation 0.97, animal model 0.69). IntOGen calls it a driver in 11 cohorts (10 activating, 1 loss-of-function), covering Adenoid Cystic Carcinoma, Colorectal Adenocarcinoma, Ovarian Epithelial Tumour, Small Cell Lung Cancer, Endometrial Carcinoma, Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumour and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9302","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9302"},{"label":"UniProt P30153","url":"https://www.uniprot.org/uniprotkb/P30153/entry"},{"label":"NCBI Gene 5518","url":"https://www.ncbi.nlm.nih.gov/gene/5518"},{"label":"Ensembl ENSG00000105568","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105568"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["endometrial","colorectal","ovarian","salivary-gland","thyroid","lung-cancer","skin-cancer","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 10 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ovarian Clear Cell Carcinoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PPP2R1A","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:9302","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9302","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P30153","url":"https://www.uniprot.org/uniprotkb/P30153/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PPP2R1A","url":"https://civicdb.org/features/4463","note":"2 evidence items, 0 assertions, 2 variants; diseases: Ovarian Clear Cell Carcinoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000105568","url":"https://platform.opentargets.org/target/ENSG00000105568/associations","note":"association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: colorectal cancer 0.54, gastric cancer 0.50, ovarian cancer 0.51, endometrial cancer 0.68, melanoma 0.55, skin cancer 0.55 (GraphQL API, CC0)"},{"label":"IntOGen PPP2R1A","url":"https://www.intogen.org/search?gene=PPP2R1A","note":"driver in 11 cohorts (Act 10, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:9302","ensembl":"ENSG00000105568","uniprot":"P30153","entrez":"5518","biology":"The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Upon interaction with GNA12 promotes dephosphorylation of microtubule associated protein TAU/MAPT. Required for proper chromosome segregation and for centromeric localisation of SGO1 in mitosis. Together with RACK1 adapter, mediates dephosphorylation of AKT1 at 'Ser-473', preventing AKT1 activation and AKT-mTOR signalling pathway. Dephosphorylation of AKT1 is essential for regulatory T-cells (Treg) homeostasis and stability. Part of the striatin-interacting phosphatase and kinase (STRIPAK) complexes. Location: Cytoplasm; Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus 19q13.41 (HGNC).","whereFound":["Endometrial cancer: Open Targets association 0.68 with endometrial cancer (MONDO_0011962); IntOGen driver in 4 cohorts (UCEC)","Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)","Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)","Salivary gland cancers: IntOGen driver in 1 cohort (ACYC)","Thyroid cancer: IntOGen driver in 1 cohort (WDTC)","Lung cancer: Open Targets association 0.56 with lung cancer (MONDO_0008903)"],"targetClass":"oncogene","prevalence":[]},"route":"/targets/ppp2r1a/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}]}}